PL2576782T3 - SiRNA i ich zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania schorzeniom oczu - Google Patents

SiRNA i ich zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania schorzeniom oczu

Info

Publication number
PL2576782T3
PL2576782T3 PL11723600T PL11723600T PL2576782T3 PL 2576782 T3 PL2576782 T3 PL 2576782T3 PL 11723600 T PL11723600 T PL 11723600T PL 11723600 T PL11723600 T PL 11723600T PL 2576782 T3 PL2576782 T3 PL 2576782T3
Authority
PL
Poland
Prior art keywords
sirna
prevention
compositions
treatment
methods
Prior art date
Application number
PL11723600T
Other languages
English (en)
Inventor
Marta Lopez-Fraga
Ana Isabel Jimenez
Tamara Martinez Valcarel
Original Assignee
Sylentis S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis S.A.U. filed Critical Sylentis S.A.U.
Publication of PL2576782T3 publication Critical patent/PL2576782T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11723600T 2010-05-27 2011-05-27 SiRNA i ich zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania schorzeniom oczu PL2576782T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10380074A EP2390327A1 (en) 2010-05-27 2010-05-27 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP11723600.0A EP2576782B1 (en) 2010-05-27 2011-05-27 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
PCT/GB2011/051007 WO2011148193A1 (en) 2010-05-27 2011-05-27 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
PL2576782T3 true PL2576782T3 (pl) 2019-09-30

Family

ID=42829386

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11723600T PL2576782T3 (pl) 2010-05-27 2011-05-27 SiRNA i ich zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania schorzeniom oczu

Country Status (20)

Country Link
US (1) US9018183B2 (pl)
EP (2) EP2390327A1 (pl)
JP (2) JP6008845B2 (pl)
KR (1) KR101585036B1 (pl)
CN (1) CN102918157B (pl)
AU (1) AU2011256978B2 (pl)
CA (1) CA2800412C (pl)
CY (1) CY1121787T1 (pl)
DK (1) DK2576782T3 (pl)
ES (1) ES2732351T3 (pl)
HR (1) HRP20191144T1 (pl)
HU (1) HUE044715T2 (pl)
LT (1) LT2576782T (pl)
MX (1) MX2012012501A (pl)
PL (1) PL2576782T3 (pl)
PT (1) PT2576782T (pl)
RS (1) RS58912B1 (pl)
SI (1) SI2576782T1 (pl)
TR (1) TR201909158T4 (pl)
WO (1) WO2011148193A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2726613T (pt) 2011-06-30 2018-10-26 Arrowhead Pharmaceuticals Inc Composições e métodos para inibição da expressão de genes do vírus da hepatite b
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
EP2865756A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
CN115957337A (zh) 2015-08-07 2023-04-14 箭头药业股份有限公司 乙型肝炎病毒感染的RNAi疗法
WO2017042238A1 (en) * 2015-09-08 2017-03-16 Sylentis Sau Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
US20200261456A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Methods for treating ocular surface pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
WO2008104978A2 (en) 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Novel sirna structures
WO2009023025A1 (en) * 2007-08-13 2009-02-19 Board Of Trustees Of Southern Illinois University Methods for treatment and prevention of ototoxicity by sirna
CA2701845A1 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures

Also Published As

Publication number Publication date
TR201909158T4 (tr) 2019-07-22
KR101585036B1 (ko) 2016-01-13
EP2576782A1 (en) 2013-04-10
AU2011256978B2 (en) 2015-06-11
JP2013528382A (ja) 2013-07-11
JP2016198104A (ja) 2016-12-01
JP6008845B2 (ja) 2016-10-19
SI2576782T1 (sl) 2019-08-30
MX2012012501A (es) 2013-02-26
PT2576782T (pt) 2019-06-28
CN102918157B (zh) 2016-06-29
WO2011148193A1 (en) 2011-12-01
KR20130043121A (ko) 2013-04-29
HUE044715T2 (hu) 2019-11-28
US9018183B2 (en) 2015-04-28
ES2732351T3 (es) 2019-11-22
US20130079389A1 (en) 2013-03-28
CN102918157A (zh) 2013-02-06
RS58912B1 (sr) 2019-08-30
CA2800412C (en) 2019-09-17
EP2390327A1 (en) 2011-11-30
HRP20191144T1 (hr) 2019-10-04
AU2011256978A1 (en) 2012-11-15
CY1121787T1 (el) 2020-07-31
DK2576782T3 (da) 2019-07-01
CA2800412A1 (en) 2011-12-01
LT2576782T (lt) 2019-07-10
EP2576782B1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
ZA201402615B (en) Prevention and treatment of ocular conditions
SI2470191T1 (sl) Postopki in sestavki za prepreäśevanje ali zdravljenje oftalmoloĺ kih stanj
PH12013500892A1 (en) Composition for use in the prevention and/or treatment of skin conditions and skin diseases
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
SG10201509279QA (en) Compositions and methods for the prevention and treatment of cancer
EP2817018A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
LT2576782T (lt) Sirnr ir jų panaudojimas būduose ir kompozicijose skirtose akių ligų gydymui ir (arba) prevencijai
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
SI2854910T1 (sl) Nivoji ceramida pri zdravljenju in preprečevanju okužb
ZA201402820B (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
GB201303868D0 (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
ZA201501494B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
ZA201304353B (en) Remedial composition and treatment methods
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
IL222482A0 (en) Methods and compositions for the treatment of fluid accumulation in and/or under the retina
ZA201502181B (en) Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP2734188A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF EYE SURFACE ALLERGIES
PL2862576T3 (pl) Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka
HUE038120T2 (hu) Transzferrin autoimmun betegségek kezelésében és/vagy megelõzésében történõ alkalmazásra
IL243237A0 (en) Methods and preparations for the treatment of fluid accumulation in and/or under the retina
PT2389936E (pt) Aminaftona para utilização no tratamento e/ou prevenção de enxaqueca
AU2012902937A0 (en) Composition for prevention and treatment of eye disorder
GB0911581D0 (en) Compositions for use in the treatment of dry eye